Home / Business and Economy / BridgeBio Stock Surges on Competitor's Setback
BridgeBio Stock Surges on Competitor's Setback
10 Jul
Summary
- Wainua trial for ATTR-CM failed its primary efficacy endpoint.
- BridgeBio's stock increased significantly following the news.
- The ATTR-CM disease affects an estimated 300,000 to 500,000 people worldwide.
On July 9, BridgeBio's stock experienced a substantial rally, jumping 14.7% after AstraZeneca and Ionis reported that their drug, Wainua, did not achieve its primary objective in a crucial Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
The CARDIO-TTRansform trial, involving 1,432 patients across 130 sites in 20 countries, aimed to assess Wainua's efficacy in treating ATTR-CM, a heart condition affecting an estimated 300,000 to 500,000 individuals worldwide. The drug, a gene silencer, was tested in conjunction with standard care, including stabilizer therapy.
However, the trial failed to demonstrate a statistically significant reduction in cardiovascular mortality and recurrent cardiovascular events compared to a placebo. This outcome had a direct impact on the ATTR-CM market, as the tested approach did not show benefit. The failure diminished prospects for Wainua, which analysts had projected could achieve $2 billion in peak sales.
Consequently, shares of AstraZeneca and Ionis declined, while U.S. companies with approved ATTR-CM treatments, such as BridgeBio and Alnylam, saw their stock prices rise. BridgeBio's market value increased by approximately $2.2 billion due to this development, signaling investor reassessment of the competitive drug development landscape.
